Editor’s note: The drugs are listed in alphabetical order.
- Amantadine hydrochloride capsule: Strides Pharma and Teva Pharmaceuticals have both discontinued the 100-milligram presentations of amantadine hydrochloride capsule, an antiviral and neurology medication, based on a business decision, while Teva’s discontinuation follows similar commercial considerations.
- Benazepril hydrochloride capsule: Aurobindo Pharma USA has discontinued the 10-, 20- and 40-milligram presentations of benazepril hydrochloride tablet, used for cardiovascular conditions.
- Gefitinib tablet: Apotex Corp. has discontinued the 250-milligram presentation of gefitinib tablet used in oncology treatments based on commercial reasons.
- Glipizide tablet, extended release: Pfizer and Teva have discontinued multiple presentations of glipizide extended-release tablet, used in endocrinology and metabolism. The decision to discontinue the products was based on business reasons.
- Idarubicin hydrochloride Injection: Pfizer has discontinued the 1-milligram/milliliter presentation of idarubicin hydrochloride injection used for oncology treatments. The product has been replaced with a new NDC number.
- Pirfenidone: Genetech has discontinued the 267-milligram presentation of pirfenidone capsule used for pulmonary/allergy treatments.
- Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated resupply by mid-February, while Alvogen has no estimated release date.
- Varenicline tartrate tablet: Mylan Pharmaceuticals has permanently discontinued multiple strengths of varenicline tablet, a medication used for addiction treatment.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
